HGS receives Complete Response Letter from FDA for ZALBIN drug

Download PDF Copy

Oct 5 2010

NewsGuard 100/100 Score

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg ZALBIN™ (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C. HGS and Novartis have decided not to develop ZALBIN further.

HGS, Human Genome Sciences and ZALBIN are trademarks of Human Genome Sciences, Inc. Other trademarks referenced are the property of their respective owners.

Source : Human Genome Sciences, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Chronic, Food, Genome, Hepatitis, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E

Comments (0)

Download PDF Copy

Suggested Reading

Genetic factors that make the bacteria behind cholera so dangerous uncovered

Genetic factors that make the bacteria behind cholera so dangerous uncovered

Study connects brain volume variations with genetic risk factors for Parkinson’s disease and ADHD

Study connects brain volume variations with genetic risk factors for Parkinson’s disease and ADHD

Genetic study uncovers key drivers of metabolic syndrome with brain tissue links

Genetic study uncovers key drivers of metabolic syndrome with brain tissue links

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

New insights on the association between genes, gut microbiota, and mental health

New insights on the association between genes, gut microbiota, and mental health

Genetic risk factors for long-COVID uncovered in a large multi-ethnic study

Genetic risk factors for long-COVID uncovered in a large multi-ethnic study

Genetic variant identified as potential predictor for severe ulcerative colitis

Genetic variant identified as potential predictor for severe ulcerative colitis

Study identifies six cancer susceptibility genes

Study identifies six cancer susceptibility genes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Researchers advance ovarian cancer detection using cfDNA fragmentomes and protein biomarkers